Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Vitamin D's hidden role in TB and fungal lung disease revealed

NCT ID NCT07516158

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether vitamin D levels are linked to certain immune markers in people with active tuberculosis (TB), with or without a chronic fungal lung infection called aspergillosis. Researchers will compare blood samples from 300 adults—including healthy volunteers—to see how vitamin D relates to the body's immune response. The goal is to better understand these diseases, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2015

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants were recruited from specialized hospitals, including a national center for infectious diseases of Uzbekistan. The study population comprised patients receiving care for pulmonary tuberculosis, including those with coexisting chronic pulmonary aspergillosis, as well as healthy individuals from the local community.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * individuals with confirmed diagnosis of pulmonary tuberculosis * individuals with confirmed diagnosis of pulmonary tuberculosis and chronoc pulmonary aspergillosis * Healthy individuals Exclusion Criteria: * individuals \<18 years old; * those using immunosuppressants, antifungals and/or antibiotics within the three-month period prior to hospitalization; * patients with chronic or acute infectious diseases (excluding PTB and CPA) and non-infectious diseases; * subjects with difficulty collecting samples; and subjects unwilling or unable to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pulmonary aspergillosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Immunology of Fungal and Parasitic Diseases

    Tashkent, Tashkent, 100151, Uzbekistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.